Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
Open Access
- 30 August 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 12141-12162
Abstract
Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.Keywords
All Related Versions
Funding Information
- National Institute of Neurological Disorders and Stroke (ZIA-NS002263)
- American Association of Colleges of Pharmacy
- National Institute on Drug Abuse (R21DA050896, Z1A DA000609)
- National Institutes of Health (HHSN-271-2018-00023-C)
- National Institute of General Medical Sciences (T34GM136492)
- National Science Foundation (CHE-1919685)
- High Point University, Fred Wilson School of Pharmacy
This publication has 54 references indexed in Scilit:
- Automated design of ligands to polypharmacological profilesNature, 2012
- N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor SelectivityJournal of Medicinal Chemistry, 2011
- The Physiology, Signaling, and Pharmacology of Dopamine ReceptorsPharmacological Reviews, 2011
- PD168077, a D4receptor agonist, reverses object recognition deficits in rats: potential role for D4receptor mechanisms in improving cognitive dysfunction in schizophreniaJournal of Psychopharmacology, 2010
- Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in ratsPsychopharmacology, 2010
- Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in ratBehavioural Pharmacology, 2008
- A-412997, a selective dopamine D4 agonist, improves cognitive performance in ratsPharmacology Biochemistry and Behavior, 2005
- Dopamine D4Ligands and Models of Receptor Activation: 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and Related Heteroarylmethylarylpiperazines Exhibit a Substituent Effect Responsible for Additional Efficacy TuningJournal of Medicinal Chemistry, 2004
- Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonistTrends in Pharmacological Sciences, 1997
- 5-(4-Chlorophenyl)-4-methyl-3-(1-(2- phenylethyl)piperidin-4-yl)isoxazole: A Potent, Selective Antagonist at Human Cloned Dopamine D4 ReceptorsJournal of Medicinal Chemistry, 1996